Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC2291 | Cilostazol |
| Potent phosphodiesterase III A (PDE3A) inhibitor (IC50 = 0.2 μM) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo. | |
| BCC2314 | Topiramate |
| Anticonvulsant. Antagonizes GluR5 kainate receptors (IC50 = 0.46 μM), acts as a positive allosteric modulator of GABAA receptor-mediated currents, inhibits Nav channels (IC50 = 48.9 μM) and inhibits L-type Ca2+ channels. Also inhibits carbonic anhydrase (CA) (Ki values are 0.1 and 0.2 μM at rat CA II and CA IV respectively), which lowers intracellular neuronal pH. | |
| BCC2326 | PF-3845 |
| Selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. Displays no activity at FAAH-2 (IC50 >10 μM). | |
| BCC2338 | VER 155008 |
| Novel adenosine-derived inhibitor of Heat Shock Protein 70 (Hsp70) (IC50 = 0.5 μM). Inhibits cell proliferation of multiple human tumor cell lines in vitro. Also binds Hsc70 and Grp78; displays selectivity against Hsp90β (IC50 >200 μM for Hsp90β). | |
| BCC2340 | BMS 299897 |
| Orally active, potent γ-secretase inhibitor (IC50 = 12 nM). Inhibits Aβ40 and Aβ42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces Aβ in the brain, plasma and cerebrospinal fluid in vivo. Exhibits no Notch toxicity. Brain penetrant. | |
| BCC2341 | Compound W |
| Inhibitor of γ-secretase; causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25). | |
| BCC2342 | Flurizan |
| Nonsteroidal anti-inflammatory drug (NSAID) that inhibits γ-secretase activity. Selectively lowers Aβ42 levels in human neuroglioma cells; displays no effect on Aβ40 levels at a concentration of 100 μM. | |
| BCC2343 | JLK 6 |
| Inhibitor of γ-secretase that selectively inhibits βAPP cleavage without affecting other γ-secretase-mediated pathways. Prevents recovery of Aβ40 and Aβ42 from HEK293 cell overexpressing wild-type or Swedish-mutated βAPP (IC50 ~ 30 μM) but displays no effect on Notch cleavage and Notch-mediated intracellular signaling. Displays no activity on BACE1, BACE2, α-secretase, the proteosome or GSK3β. | |
